PolyPeptide Group (Hangzhou): difference between revisions
Diff·revision 20 → 21·22:46, 18 Jan 2026
Difference between revision 20 and revision 21 of PolyPeptide Group (Hangzhou). 12 lines changed; the page grew by 1,288 bytes.
| Revision 20 — 04:46, 10 Jan 2026 SemaglutideSasha (talk) expand §Distribution and dispatch 14,476 bytes +61 | Revision 21 — 22:46, 18 Jan 2026 MetricMabel (talk) expand the product-scope row in the infobox 15,764 bytes +1,288 | ||
|---|---|---|---|
| 92 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} | 92 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} |
| 93 | 93 | ||
| + | 94 | PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.{{r|tally}} | |
| + | 95 | ||
| + | 96 | == Regulatory position and legal status == | |
| + | 97 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | |
| + | 98 | ||
| + | 99 | Material labelled [[Research use only|for research use only]] is outside the regulatory framework that governs medicines. Its identity, purity, sterility and [[Bacterial endotoxin test|endotoxin]] content are not assured by any regulator, and a [[Certificate of analysis|certificate of analysis]] issued by a supplier is a claim by that supplier rather than an independent finding.{{r|ruo,usp1503}} | |
| + | 100 | ||
| 94 | == References == | 101 | == References == |
| 95 | {{reflist}} | 102 | {{reflist}} |
| ⋮ | ⋮ | ||
| 101 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 108 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 102 | 109 | ||
| + | 110 | == Further reading == | |
| + | 111 | * [[Project:Vendor notability]] — the criteria under which this article exists, and what supplier articles may not contain. | |
| + | 112 | * [[Project:Sourcing guidelines]] — how test reports and community tallies are cited on this wiki. | |
| + | 113 | ||
| 103 | == See also == | 114 | == See also == |
| 104 | * [[Certificate of analysis]] | 115 | * [[Certificate of analysis]] |
| ⋮ | ⋮ | ||
| 108 | * [[Research use only]] | 119 | * [[Research use only]] |
| 109 | * [[Peptide supply chain]] | 120 | * [[Peptide supply chain]] |
| + | 121 | * [[Blind sampling]] | |
| 110 | 122 | ||
| 111 | {{DEFAULTSORT:PolyPeptide Group (Hangzhou)}} | 123 | {{DEFAULTSORT:PolyPeptide Group (Hangzhou)}} |